RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participantsPlasma exposures ...

Prilenia and Ferrer will unveil their planned pivotal Phase 3 study of pridopidine in ALS at the upcoming Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) 2025 Annual Meeting, Florida, Octob ...

By Dr. Isaac Mawuko ADUSU In Ghana, the conversations about including people with disabilities have intensified as the ...

In CBeyond TM, the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo (-1.52% vs. -0.26 for placebo, mITT 1 ). Preliminary pharmacokinetic analysis ...